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Review
Erythrocytes in multiple sclerosis  forgotten
contributors to the pathophysiology?
Kira Groen, Vicki E Maltby, Katherine A Sanders, Rodney J Scott, Lotti Tajouri and
Jeannette Lechner-Scott
Abstract
Multiple sclerosis (MS) is an autoimmune disease characterised by lymphocytic infiltration of the central
nervous system and subsequent destruction of myelin and axons. On the background of a genetic pre-
disposition to autoimmunity, environmental triggers are assumed to initiate the disease. The majority of
MS research has focused on the pathological involvement of lymphocytes and other immune cells, yet a
paucity of attention has been given to erythrocytes, which may play an important role in MS pathology.
The following review briefly summarises how erythrocytes may contribute to MS pathology through
impaired antioxidant capacity and altered haemorheological features. The effect of disease-modifying
therapies on erythrocytes is also reviewed. It may be important to further investigate erythrocytes in MS,
as this could broaden the understanding of the pathological mechanisms of the disease, as well as
potentially lead to the discovery of novel and innovative targets for future therapies.
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Introduction
Multiple sclerosis (MS) is a debilitating inflamma-
tory disease of the central nervous system (CNS),
affecting around 2.5 million individuals worldwide.
It is more prevalent in females, typically diagnosed
in the third and fourth decades of life, and reduces
life expectancy by 5 to 10 years.1 Lymphocytes are
known to play a role in MS pathology, but erythro-
cytes may also be involved. The role of erythrocytes
in MS pathophysiology is poorly understood, yet
erythrocytes may contribute to the disease through
impaired antioxidant capacity and altered
haemorheology.
Erythrocytes  a brief overview
Mature erythrocytes are observed as anucleate bicon-
cave disks that do not contain organelles. Their main
function is gas transport and consequently around
97% of the erythrocyte is occupied by haemoglobin.
Nevertheless, erythrocytes contain antioxidant
enzymes and structural proteins. Due to the lack of
mitochondria, erythrocytes rely on anaerobic gly-
colysis for energy production. Erythrocytes originate
in the bone marrow from pluripotent haematopoietic
stem cells and are part of the myeloid lineage.
Homeostatic erythropoiesis is essential to ensure
adequate blood viscosity and prevent hypoxia.2
Mature erythrocytes have an average lifespan of
100120 days;2 yet reduced erythrocyte lifespans
may be observed in individuals with elevated
levels of oxidative stress.3
Erythrocytes may contribute to the pathophysio-
logical mechanisms of MS through impaired antioxi-
dant capacity and altered haemorheology, leading to
increased oxidative stress in the periphery and poten-
tial ischaemic tissue damage respectively.
Oxidative stress in MS
In addition to the inflammatory component, MS may
also be affected by oxidative stress in both the CNS
and periphery; a topic that has been recently
reviewed.4 Peripheral oxidative stress in MS has
been evidenced by increased levels of erythrocyte
lipid peroxidation and erythrocyte advanced oxida-
tion protein products in MS patients compared to
healthy controls.57 Oxidative stress increases
between patients with clinically isolated syndrome
(CIS) and patients with relapsingremitting MS
(RRMS).5 The age of the CIS patients (1757,
median: 37.5 years) recruited for this study did not
significantly differ from the age of RRMS patients
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(2358, median: 40 years), it is therefore unlikely that
age was a confounder. The documented differences in
oxidative stress may be attributed to ongoing inflam-
mation.5 Further, oxidative stress correlates with
higher Expanded Disability Status Scale (EDSS)
scores, lesion load, and disease duration in RRMS.5
Malondialdehyde, a by-product of lipid peroxidation,
was also positively correlated with disease duration,
EDSS scores, and lesion load.5 These correlations
suggest a link between oxidative stress in MS and
disease severity; however, oxidative stress is not dis-
ease specific and has been observed as a part of
ageing.8 Increased levels of oxidative stress may be
the result of inflammation not necessarily intrinsic to
MS pathology. This is supported by a study that com-
pared RRMS patients in relapse and in remission.
Oxidative stress appears to be increased in relapse,
but unchanged during remission compared to healthy
controls. Although the sample size of the above-men-
tioned study was small (18 RRMS patients and 7
healthy controls),9 the same patients were analysed
in relapse and remission, strengthening the reliability
of the findings. However, a larger cohort should be
assessed. The presence of oxidative stress in the per-
iphery in secondary progressive MS (SPMS)
patients,7 in whom the disease is thought to be more
neurodegenerative and confined to the CNS,1 supports
the hypothesis that oxidative stress is part of the
pathogenesis and not merely a result of tissue destruc-
tion. This study also had a small number of SPMS
(n¼ 16) and healthy controls (n¼ 13).7 To determine
if oxidative stress actually affects MS pathology, fur-
ther studies with larger cohorts and appropriate patho-
logical and age-matched controls are required.
Impaired erythrocyte antioxidant capacity in MS
Decreased erythrocyte antioxidant capacity in MS
may be explained by lower erythrocyte antioxidant
enzyme activities in MS patients compared to healthy
controls. Relevant antioxidant enzymes may include
glutathione peroxidase (GPx), superoxide dismutase
(SOD) and catalase.
Erythrocyte GPx
GPx protects the body from oxidative damage
by catalysing the reduction of lipid hydroperoxides
to their corresponding alcohols, as well as the reduc-
tion of hydrogen peroxide to water.10 Multiple
studies found erythrocyte GPx activity to be
decreased in MS patients (n¼ 2457) compared to
healthy controls (n¼ 2469)1113 and patients with
other neurological diseases, including cerebrovascular
syndrome (n¼ 8), lumbar cervical discopathy (n¼ 6),
amyotrophic lateral sclerosis (n¼ 4), Guillain-Barre´
syndrome (n¼ 3) and others (n¼ 9)14 (Figure 1).
Mehlert et al. did not find a decrease in GPx activity
in MS patients (n¼ 12) compared to healthy controls
(n¼ 11) or controls with other neurological diseases
(n¼ 12, neurological diseases not disclosed).15
However, the sample recruited by Mehlert et al.15
was smaller than the sample recruited by studies
that reported significant differences1114 and sample
size may explain the discrepancy. Erythrocyte GPx
activity was lower in RRMS patients than in CIS
patients, and lower in CIS patients than in healthy
controls.13 Additionally, erythrocyte GPx activity
was lower in SPMS patients than in healthy controls.7
In contrast, lymphocytes, granulocytes and platelets
appear to have normal GPx activity in MS.16 Thus,
reduced activity of this enzyme supports the hypoth-
esis of impaired erythrocyte antioxidant capacity in
MS; nonetheless, failure to control for selenium
levels may have impacted on study results as selenium
is vital for GPx activity.10 Future investigations
should consider measuring patients’ selenium levels
and controlling for this confounder.
In addition, erythrocyte glutathione, one of the
cofactors of GPx,10 was found to be decreased in
RRMS patients and patients with CIS compared to
healthy controls,13 negatively correlating to disease
severity and lesion load both in RRMS and CIS
patients. This study also found erythrocyte glutathi-
one levels were negatively correlated with disease
duration in CIS patients.13 Interestingly, decreased
glutathione levels have also been identified through
magnetic resonance spectroscopic imaging both in
the grey matter and white matter of MS patients
compared to healthy controls.17
Erythrocyte SOD
SOD catalyses the dismutation of the superoxide rad-
ical to either hydrogen peroxide or oxygen, acting as
an antioxidant enzyme that protects against oxidative
stress.18 Compared to healthy controls, erythrocyte
SOD activity, measured spectrophotometrically, is
lower in SPMS patients,7 yet greater in RRMS and
CIS patients5,6 than in healthy controls. Erythrocyte
SOD activity is greatest in CIS patients5 (Figure 1).
Erythrocyte SOD activity is negatively correlated
with EDSS scores across studied disease subtypes.5,7
While the studies had small numbers, appropriate
age-matching of controls and MS subtypes excludes
age as a confounding factor and strengthens the find-
ings. Decreased activity of this enzyme in SPMS
supports impaired erythrocyte antioxidant capacity
in the chronic neuro-inflammatory stage of disease,
but not in CIS or RRMS. This potentially indi-
cates that initial increases in oxidative stress can be
compensated for by SOD, but SOD antioxidant
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mechanisms gradually fail as the disease progresses,
leading to ongoing neuronal damage. This is sup-
ported by the negative correlations between erythro-
cyte SOD activity and multiple markers of disease
severity (disease duration, lesion load, and EDSS
scores).5 Erythrocyte SOD activity may be improved
with adrenocorticotropic hormone (ACTH) therapy19
(Figure 1), a historic treatment for MS.
Erythrocyte catalase
Catalase protects against oxidative damage by con-
verting hydrogen peroxide to water and oxygen.20
Interestingly, erythrocyte catalase activity was
found to be increased in patients with SPMS com-
pared to healthy controls,7 yet decreased in RRMS19
(Figure 1). An increase in this enzyme in SPMS may
indicate a compensation mechanism to combat lower
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Figure 1. Erythrocyte antioxidant enzymes in multiple sclerosis. The figure shows (a) three of the erythro-
cyte antioxidant enzymes  superoxide dismutase (SOD), glutathione peroxidase (GPx) and catalase 
and the reaction they catalyse to combat the effects of oxidative stress. Activities of erythrocyte SOD,
GPx and catalase are altered in clinically isolated syndrome, relapsingremitting MS, and secondary
progressive MS compared to healthy controls. Nitric oxide synthase (NOS) catalyses the synthesis of nitric
oxide, which may contribute to oxidative stress following the reaction with superoxide resulting in perox-
ynitrite. (b) Adrenocorticotropic hormone (ACTH) and (c) melatonin enhance and suppress various erythro-
cyte enzymes.
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levels of erythrocyte GPx, as both enzymes protect
against hydrogen peroxide.10,20 However, this requires
further investigation. Treatment with ACTH also
improves catalase activity19 (Figure 1). Potential bene-
fits in progressive MS should be further investigated.
Treatment to combat oxidative stress in MS
Melatonin is a powerful antioxidant.21 Melatonin
increased erythrocyte SOD activity and erythrocyte
GPx activity in SPMS patients supplemented with
10 mg melatonin daily for 30 days7 (Figure 1).
Melatonin supplementation also resulted in a
decrease in erythrocyte membrane lipid peroxidation
in SPMS patients.7 Furthermore, melatonin has been
shown to contribute to the seasonality of MS
relapses, as well as ameliorating symptoms of the
MS experimental model, experimental autoimmune
encephalomyelitis.22 Interestingly, these findings sug-
gest that melatonin supplementation may improve
antioxidant capacity in SPMS patients. This is particu-
larly significant, as there are currently no treatments
available for SPMS. Supplementation with antioxi-
dant vitamins may also be beneficial in MS and
should be more thoroughly investigated, as decreased
antioxidant vitamin levels have been reported in MS
patients compared to healthy controls.23 Whole-body
cryotherapy has also been found to reduce oxidative
stress in MS patients. Whole-body cryotherapy con-
sists of exposure to extremely low temperatures,
during which less oxygen is required, reducing oxida-
tive stress.24
Other erythrocyte enzymes
Other erythrocyte enzymes have been studied in MS.
For example, erythrocyte adenosine deaminase
(ADA) activity was lower in MS patients than in
healthy controls. ACTH treatment restored ADA
activity to healthy levels, and increased the enzyme’s
activity above that of healthy controls.25 The authors
hypothesised that increased ADA activity following
ACTH treatment may be due to a reduction in oxi-
dative stress and consequently less damage to the
erythrocyte membrane and membrane-associated
enzymes such as erythrocyte ADA.25
While there appear to be differences in the activities
of several enzymes, possibly reflecting changes in
concentration or enzyme damage, a previous study
identified no differences between MS patients
and control participants erythrocyte proteins, demon-
strating that all proteins found in control erythrocytes
were also found in MS erythrocytes and vice-versa.26
There are conflicting studies reporting on activity in
erythrocyte 2’, 3’-cyclic nucleotide 3-phosphohy-
drolase (CNP).27,28 Decreased CNP activity in MS
erythrocyte membranes was observed only in the pre-
liminary study, for which only five MS patients and
five healthy controls were recruited.28 Consequently,
observed differences in CNP activity between MS
patients and healthy controls are unlikely to be sig-
nificant. No significant differences were found in
erythrocyte pyrimidine 5’-nucleotidase activity.29
Haemorheology  a brief overview
Haemorheology is the study of blood fluidity. Blood
fluidity is not constant throughout the circulatory
system. At higher shear rates observed in arteries,
blood viscosity decreases, while venous blood sub-
jected to lower shear rates is more viscous. This dis-
tinct haemodynamic characteristic can be attributed to
erythrocyte deformability at higher shear rates, and
erythrocyte aggregation at lower shear rates.
Erythrocyte deformability is facilitated by the distinct
plasma membrane composition, as well as lack of a
nucleus and organelles, permitting transit of bicon-
cave erythrocytes to ellipsoidal structures at higher
shear rates. At lower shear rates, erythrocytes regain
their biconcave shape and aggregate, forming revers-
ible rouleaux.30
Alterations in haemorheology MS
Total blood viscosity was found to be increased at
higher and lower shear rates in MS patients com-
pared to healthy individuals31 and pathological con-
trols suffering from other neuro-inflammatory and
neurodegenerative disorders.32 Several alterations
in erythrocyte haemorheology have been studied
and reported in MS; however, results are conflicting
and the mechanisms responsible for increased blood
viscosity in MS patients are poorly understood.31,32
Impaired flow in the cerebral microcirculation due to
an increase in blood viscosity may lead to stasis of
blood in these vessels, which causes ischaemic tissue
damage. An inflammatory response to this ischaemic
tissue damage then results in impairment of the
vessel wall, increasing its permeability and poten-
tially enabling inflammatory cells and mediators to
infiltrate the CNS.33,34 The recent discovery of
lymphatic vessels in the brain challenges the para-
digm that the CNS is ‘immune-privileged’.35 Thus,
disruption of blood vessel walls may not be required
for immune infiltration to occur. While there is some
evidence that decreased blood fluidity is associated
with decreased tissue perfusion, measurements of
rheological parameters fail to take into account
in vivo compensation mechanisms, such as vaso-
motor control. Despite questions about the implica-
tions of haemorheological alterations in vivo, strong
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associations have been reported between altered
blood fluidity and disease processes.36
By ruling out alterations in haematocrit,31 extreme
leucocytosis37 and increased plasma viscosity32 alter-
ations in blood viscosity are likely to be accounted
for by altered erythrocyte aggregation and/or
deformability.36
Erythrocyte deformability
Simpson et al.31 indicated impaired erythrocyte
deformability by early filtration experiments.
Impaired erythrocyte deformability may be causing
increased blood viscosity in MS patients. However,
Pollock et al. did not find impaired erythrocyte
deformability in MS patients.38 Both studies31,38
were of small size, but Simpson et al. failed to con-
trol for fasting blood lipids and blood sugar, and
some MS patients were receiving steroids at the
time of sample collection.31 As leucocyte contamin-
ation can cause blockage of the filter pores used for
early blood filtration experiments and new and
improved technology has been developed since the
original studies, impaired erythrocyte deformability in
MS should be reinvestigated. Morphological changes
to erythrocytes, (macrocytes and echinocytes) are
positively correlated to MS disease severity31,39,40
and may impair erythrocyte deformability.41
Red cell distribution width (RDW) is a measure of the
size and volume of erythrocytes and influences
deformability.42 One study found that RRMS patients
(n¼ 109) have increased RDW compared to healthy
controls (n¼ 130). This may underlie altered erythro-
cyte deformability in MS. Elevated RDW was found
to be positively related to EDSS scores.42 This study
had a reasonable sample size, but failed to control for
other potential confounders that influence RDW and
lacked appropriate pathological controls. Further
investigation in the use of RDW as a biomarker is
required.
Oxidative stress in the peripheral circulation of MS
patients24,43 may further impede erythrocyte deform-
ability through erythrocyte membrane lipid peroxi-
dation.7,36 Nonetheless, more research into impaired
erythrocyte deformability in MS patients is needed
as better technology has been developed since the
original studies.
Erythrocyte aggregation
MS is inflammatory driven;1 inflammatory markers,
including fibrinogen (essential for blood clot forma-
tion), are known to influence haemorheology.36
Thus, there is a possibility that increased erythrocyte
aggregation is associated with the haemorheological
changes seen in MS.
Despite inflammatory events, RRMS patients do not
appear to have elevated fibrinogen levels in the
remitting phase.44 However, D-dimer levels, turn-
over markers of cross-linked fibrin, are elevated44,45
and low fibrinogen levels during remission (MS
patients vs. controls) do not exclude the possibility
of increased fibrinogen levels during relapse,
especially considering the role of fibrinogen in MS
pathology, where fibrin is involved in the release
of cytokines and activation of microglia in the
CNS.46,47
Potential interference of platelets
Platelets play an essential role in the coagulation
cascade and are abundant in MS lesions.48 While
platelets themselves do not directly impact on
erythrocyte aggregation, they influence thrombotic
processes, which may interfere with haemorheologi-
cal studies.36,49 Blood clot formation in the cerebral
microcirculation due to increased platelet counts
supports the idea of ischaemic tissue injury.33
Erythrocyte NOS  potential implications for
haemorheology
Erythrocytes may influence blood fluidity through
expression of erythrocyte NOS. Erythrocytes contain
messenger RNA (mRNA) for NOS and other pro-
teins,50 as well as functional NOS in both their mem-
brane and cytoplasm.51 NOS activity in MS patients
has not yet been investigated; however, the nitric
oxide (NO) produced by NOS acts as a vasodilator
under hypoxic conditions.52,53 Therefore, decreased
NOS expression during erythrocyte development in
MS may lead to decreased NO levels and hence cere-
bral vasoconstriction, resulting in ischaemic tissue
injury.33 Moreover, erythrocyte-derived NOS has
been shown to regulate erythrocyte deformability
and platelet aggregation. Kleinbongard et al. hypoth-
esised that NOS influences erythrocyte deformability
through altering functional characteristics of the
erythrocyte membrane.51 Therefore, a reduction in
this enzyme might further lead to impaired erythro-
cyte deformability and enhanced platelet aggrega-
tion, two features that may also contribute to
ischaemic tissue injury. Alternatively, if erythrocyte
NOS activity were increased in MS, it may be con-
tributing to the oxidative stress observed in MS
through NO (Figure 1). However, until erythrocyte
NOS activity is measured in MS, no conclusions can
be drawn in this area.
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Erythrocyte complement receptor (CR1)
MS patients’ erythrocytes appear to have lower CR1
expression than healthy controls.54 Erythrocyte CR1
mediates immune-adherence clearance of immune
inflammatory particles (immune complexes, apoptotic
debris and microbes).55 Consequently, decreased
levels of this CR1 may result in increased accumula-
tion of inflammatory particles in the circulation, lead-
ing to potential inflammatory damage to the
vasculature and surrounding tissues.
Serum myeloperoxidase (MPO) and MS
MPO, a haeme containing enzyme mainly synthe-
sised by neutrophils, is released in response to
inflammation. It catalyses the generation of reactive
oxygen species (ROS), as well as the consumption of
NO,56 thereby contributing to oxidative damage and
potentially ischaemic damage through the consump-
tion of the vasodilator NO. Erythrocytes have been
found to bind MPO,57,58 which impaired their
deformability58 and altered vascular resistance sys-
temically.57 While increased levels of MPO have
been observed in the lesions of MS patients59 and
serum of an Asian MS cohort,60 no data are available
regarding erythrocyte-bound MPO in multiethnic
MS cohorts.
Disease-modifying therapies (DMTs) and
erythrocytes
Depending on their mechanism of action, DMTs
have the potential to affect circulating erythrocytes.
Treatment with natalizumab results in detection
of previously undetected erythroblasts in the periph-
eral blood of RRMS patients. Other haematopoietic
precursors, namely neutrophil precursors, are
also increased after natalizumab treatment.6163
Mitoxantrone, fingolimod, and dimethyl fumarate
all have the potential to cause eryptosis (erythro-
cyte-specific apoptosis).6466 Interferon-ß treatment
appeared to reduce RDW and thus may counteract
the increased RDW observed in RRMS patients.42
Conclusions and future directions
As previous research has shown, erythrocytes are
altered in the various subtypes of MS and potentially
contribute to the oxidative stress in MS through
impaired antioxidant capacity. Furthermore, altered
haemorheological features observed in MS may be
the result of altered erythrocyte phenotypes.
Differences in erythrocyte RDW between MS
patients and controls42 could be associated with
altered erythrocyte deformability and hence altered
haemorheology. Additionally, increased erythrocyte
aggregation due to greater levels of inflammation in
the periphery of MS patients may further contribute
to altered haemorheology in MS patients. Both MS
pathology and DMTs appear to affect circulating
erythrocytes. Further research in this area is needed
to establish the implications of altered erythrocytes
for MS patients. Many of the studies on erythrocytes
in MS were of low power and lacked pathological
controls, which may confound the results.
It will be beneficial to confirm the results in larger
cohorts, with appropriately matched (age, gender,
physical activity level, body composition and diet)
healthy and pathological controls. Activities of
erythrocyte antioxidant enzymes as well as potential
mechanisms of altered erythrocyte enzyme activities
in MS subtypes need to be investigated. Alterations
in blood viscosity in MS subtypes need to be con-
firmed and potential mechanisms, including but not
limited to erythrocyte involvement, need to be stu-
died in further detail. NOS activity should also be
investigated in MS and compared to healthy and
pathological controls as it may affect both haemor-
heological characteristics and antioxidant capacity of
erythrocytes in MS.
Investigation of the role of erythrocytes in MS may
lead to the discovery of further specific differences
that could be exploited as biomarkers of the disease
and aid patient stratification. Additionally, research
on the role of erythrocytes in MS may broaden the
understanding of the pathological mechanisms of
this complex and heterogeneous disease and this in
turn may lead to the discovery of novel and innova-
tive targets for future therapies that may greatly
improve patients’ quality of life.
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